A K. Ritchey
Advanced in Acute Lymphoblastic Leukemia (ALL)

Dr. A K. Ritchey

Pediatric Hematology Oncology
UPMC
UPMC Children's Hospital Of Pittsburgh, Pediatric Hematology/Oncology
4401 Penn Avenue, Floor 3, 
Pittsburgh, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Advanced in Acute Lymphoblastic Leukemia (ALL)
UPMC
UPMC Children's Hospital Of Pittsburgh, Pediatric Hematology/Oncology
4401 Penn Avenue, Floor 3, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

A. Kim Ritchey, MD, is a pediatric hematologist/oncologist and is certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics. He is vice-chair of International Affairs of the Department of Pediatrics at UPMC Children’s Hospital of Pittsburgh and is professor of pediatrics at the University of Pittsburgh School of Medicine. He received his medical degree from the University of Cincinnati School of Medicine and completed his pediatric residency at Johns Hopkins Hospital, followed by his fellowship in pediatric hematology/oncology at Yale University. Dr. Ritchey’s clinical interests include all aspects of pediatric hematology and oncology. His career focus is pediatric leukemia and coagulation disorders. He has numerous publications in peer-reviewed journals as well as book chapters and has presented both locally and nationally. He is a member of the American Society of Pediatric Hematology/Oncology where he served as president, as well as the American Society of Hematology, and the American Society of Clinical Oncology.

Dr. Ritchey is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hemophilia B, Hemophilia A, and Leukemia.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 8 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Pediatric Hematology Oncology
Licenses
Specialist in PA
Board Certifications
American Board Of Pediatrics
American Board Of Pediatrics
Fellowships
Yale New Haven Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 12 Less Insurance Carriers -

Locations

UPMC Children's Hospital of Pittsburgh, Pediatric Hematology/Oncology
4401 Penn Avenue, Floor 3, Pittsburgh, PA 15224
Call: 412-692-5055

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


19 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Enrollment Status: Completed
Publish Date: November 20, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Other
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2025
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Other
Key Adverse Events After Childhood Cancer
Key Adverse Events After Childhood Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Other
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Procedure, Drug
Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 2
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment Status: Completed
Publish Date: December 07, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Other
Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
Enrollment Status: Withdrawn
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Enrollment Status: Completed
Publish Date: July 19, 2018
Intervention Type: Other
View 18 Less Clinical Trials

24 Total Publications

Neonatal Portal Vein Thrombosis: A Retrospective Study of Management and Follow-Up at One Institution.
Neonatal Portal Vein Thrombosis: A Retrospective Study of Management and Follow-Up at One Institution.
Journal: Pediatric blood & cancer
Published: October 09, 2024
View All 24 Publications
Similar Doctors
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Lindsay J. Blazin
Pediatric Hematology Oncology
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Lindsay J. Blazin
Pediatric Hematology Oncology
4401 Penn Ave, AOB Suite 5400, 
Pittsburgh, PA 
 (0.1 miles away)
412-692-5285
Languages Spoken:
English
See accepted insurances

Lindsay Blazin is a Pediatric Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Blazin is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), and Bone Marrow Aspiration.

Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Lubna S. Mehyar
Pediatric Hematology Oncology
Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Lubna S. Mehyar
Pediatric Hematology Oncology
1 Medical Center Dr, 
Morgantown, WV 
 (56.2 miles away)
304-598-4000
Languages Spoken:
English
See accepted insurances

Lubna Mehyar is a Pediatric Hematologist Oncology provider in Morgantown, West Virginia. Dr. Mehyar is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Von Gierke Disease, Febrile Neutropenia, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

Jenny Ruiz
Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Jenny Ruiz
Pediatric Hematology Oncology
Experienced in Acute Lymphoblastic Leukemia (ALL)
Dr. Jenny Ruiz
Pediatric Hematology Oncology

Pediatric Hematology Oncology In Lawrenceville

4401 Penn Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
412-692-5055
Languages Spoken:
English
See accepted insurances

Jenny Ruiz, MD, specializes in pediatric hematology oncology and is board certified in pediatric hematology-oncology and pediatrics by the American Board of Pediatrics. She practices at UPMC Children's Hospital of Pittsburgh, Pediatric Hematology/Oncology and is affiliated with UPMC Magee-Womens Hospital. Dr. Ruiz completed her fellowship at Children's Hospital of Philadelphia, residency at Columbia University, and medical education at Columbia University College of Physicians and Surgeons. Dr. Ruiz is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Leukemia, Acute Lymphoblastic Leukemia (ALL), Ewing Sarcoma, and Osteosarcoma.

VIEW MORE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritchey's expertise for a condition
ConditionClose
      • Advanced
      • Acute Lymphoblastic Leukemia (ALL)
        Dr. Ritchey is
        Advanced
        . Learn about Acute Lymphoblastic Leukemia (ALL).
        See more Acute Lymphoblastic Leukemia (ALL) experts
      • Hemophilia A
        Dr. Ritchey is
        Advanced
        . Learn about Hemophilia A.
        See more Hemophilia A experts
      • Hemophilia B
        Dr. Ritchey is
        Advanced
        . Learn about Hemophilia B.
        See more Hemophilia B experts
      • Leukemia
        Dr. Ritchey is
        Advanced
        . Learn about Leukemia.
        See more Leukemia experts
      • Experienced
      • Chromosome 7p Deletion
        Dr. Ritchey is
        Experienced
        . Learn about Chromosome 7p Deletion.
        See more Chromosome 7p Deletion experts
      • Hemophilic Arthropathy
        Dr. Ritchey is
        Experienced
        . Learn about Hemophilic Arthropathy.
        See more Hemophilic Arthropathy experts
      • Infantile Neutropenia
        Dr. Ritchey is
        Experienced
        . Learn about Infantile Neutropenia.
        See more Infantile Neutropenia experts
      • Juvenile Myelomonocytic Leukemia (JMML)
        Dr. Ritchey is
        Experienced
        . Learn about Juvenile Myelomonocytic Leukemia (JMML).
        See more Juvenile Myelomonocytic Leukemia (JMML) experts
      • Mast Cell Activation Syndrome (MCAS)
        Dr. Ritchey is
        Experienced
        . Learn about Mast Cell Activation Syndrome (MCAS).
        See more Mast Cell Activation Syndrome (MCAS) experts
      • RASopathies
        Dr. Ritchey is
        Experienced
        . Learn about RASopathies.
        See more RASopathies experts
      View All 7 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

          Close
          0 / 1000

          Please provide us with the below insurance information:

                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.